

***Listing of the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Previously presented) A method of reducing the viability of a tumor cell, comprising administering to the tumor cell a virus, such that the virus is delivered to the tumor cell,

wherein said virus is a vesicular stomatitis virus and said tumor cell is a hematopoietic tumor cell and

wherein the virus is contained in a cell infected with the virus and the administering comprises administering the virus-infected cell.

2-5. (Cancelled)

6. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a leukemia, a lymphoma, or a myeloma.

7. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a leukemia.

8. (Original) The method of claim 7, wherein the leukemia is acute myelogenous leukemia.

9. (Original) The method of claim 7, wherein the leukemia is chronic myelogenous leukemia.

10. (Original) The method of claim 7, wherein the leukemia is promyelocytic leukemia.

11. (Original) The method of claim 7, wherein the leukemia is T cell leukemia.

12. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a lymphoma.

13. (Previously presented) The method of claim 1, wherein the hematopoietic tumor cell is a myeloma.

14-18. (Cancelled)

19. (Original) The method of claim 1, wherein the tumor cell is PKR<sup>-/-</sup>; STAT1<sup>-/-</sup>; or both PKR<sup>-/-</sup> and STAT1<sup>-/-</sup>.

20-23. (Cancelled)

24. (Previously presented) The method of claim 1, further comprising administering interferon to the tumor cell prior to administering VSV, such that the interferon is delivered to the tumor cell.

25. (Previously presented) The method of claim 1, wherein the virus is unable to inactivate PKR activity within the tumor cell.

26. (Previously presented) The method of claim 1, wherein the virus is an attenuated strain of vesicular stomatitis virus.

27. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M1.

28. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M2.

29. (Previously presented) The method claim 1, wherein the virus is vesicular stomatitis virus strain M3.

30. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M4.

31. (Previously presented) The method of claim 1, wherein the virus is vesicular stomatitis virus strain M5.

32. (Previously presented) The method of claim 1, wherein the tumor cell is in a mammalian subject.

33. (Previously presented) The method of claim 32, wherein the mammalian subject is a human.

34. (Previously presented) The method of claim 32, wherein the administering comprises administering the virus-infected cell to the subject by a route selected from intratumorally, intravenously and intraperitoneally.

35. (Previously presented) A method of reducing the viability of a tumor cell within a population of cells comprising administering a vesicular stomatitis virus to the population of cells, such that the virus is delivered to the population of cells,

wherein the virus is contained in a cell infected with the virus and the administering comprises administering the virus-infected cell,

wherein the population of cells comprises hematopoietic tumor cells and non-tumor cells and

wherein the virus is able to selectively reduce the viability of the hematopoietic tumor cells.

36. (Original) The method of claim 35, wherein the virus is unable to inactivate PKR activity in the tumor cell.

37. (Previously presented) The method of claim 36, further comprising treating the population of cells with interferon prior to administering the virus.

38-63. (Cancelled)

64. (Previously presented) The method of claim 35, wherein the hematopoietic tumor cells are leukemia cells.

65. (Previously presented) The method of claim 64, wherein the leukemia cells are acute myelogenous leukemia cells.

66. (Previously presented) The method of claim 64, wherein the leukemia cells are chronic myelogenous leukemia cells.

67. (Previously presented) The method of claim 64, wherein the leukemia cells are promyelocytic leukemia cells.

68. (Previously presented) The method of claim 64, wherein the leukemia cells are T cell leukemia cells.

69. (Previously presented) The method of claim 35, wherein the hematopoietic tumor cells are lymphoma cells.

70. (Previously presented) The method of claim 35, wherein the hematopoietic tumor cells are myeloma cells.

71. (Previously presented) The method of claim 35, wherein the tumor cells are PKR<sup>-/-</sup>; STAT1<sup>-/-</sup>; or both PKR<sup>-/-</sup> and STAT1<sup>-/-</sup>.

72. (Previously presented) The method of claim 35, wherein the virus is an attenuated strain of vesicular stomatitis virus.

73. (Previously presented) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M1.

74. (Previously presented) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M2.

75. (Previously presented) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M3.

76. (Previously presented) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M4.

77. (Previously presented) The method of claim 35, wherein the virus is vesicular stomatitis virus strain M5.

78. (Previously presented) The method of claim 35, wherein the administering of the vesicular stomatitis virus to the population of cells is performed *in vitro*.

79. (Previously presented) The method of claim 32, wherein the mammalian subject is a non-human mammal.

80. (Previously presented) The method of claim 32, further comprising treating the mammalian subject with an interferon.